Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

XY-018 is an inverse agonist of retinoic acid receptor-related orphan receptor γ (RORγ).1 It induces RORγ transcriptional activity in a reporter assay using LNCaP cells (IC50 = 0.19 µM). XY-018 selectively induces RORγ transcriptional activity over RORα transcriptional activity in HEK293T cells (IC50 = 7.57 µM). It reduces the proliferation of androgen receptor-positive LNCaP, 22Rv1, and C4-2B and androgen receptor-negative DU145 and PC3 prostate cancer cells (IC50s = 5.14, 9, 9.2, 28.43, and 11.14 µM, respectively). XY-018 (40 mg/kg per day) decreases tumor volume and induces apoptosis in a patient-derived xenograft (PDX) mouse model of castration-resistant prostate cancer.2
WARNING This product is not for human or veterinary use.
1. Discovery and characterization of XY101, a potent, selective, and orally bioavailable RORγ inverse agonist for treatment of castration-
2. Targeting feedforward loops formed by nuclear receptor RORγ and kinase PBK in mCRPC with hyperactive AR signaling. Cancers (Basel) 13(7), 1672 (2021).